Clasado Biosciences has announced the publication of new peer-reviewed research, done in association with Cryptobiotix, pioneers in preclinical gastrointestinal research.
The study, "Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses," published in Metabolites, presents a significant development for formulators in the health and nutrition market, particularly those working with compact or multi-ingredient formats such as capsules or tablets.
The research, using Cryptobiotix’s SIFR (cipher) technology, demonstrates that Bimuno GOS delivers a statistically significant bifidogenic effect from 380 mg of active GOS, supporting a measurable increase in beneficial bacteria.
This change was shown to correlate with a rise in key short-chain fatty acids (SCFAs), alongside a significant decrease in gut pH within 6 hours ... with further enhancements at 24 hours.
The study attributes this dose efficacy to the unique structure and selectivity of Bimuno GOS, noting that similar results may not necessarily be achievable with other GOS or prebiotics.
Also of importance is that the results were observed across a wide biological range of hosts, indicating reliable effects across healthy adult populations and reflecting a real-world situation.
“This is a very exciting moment for the prebiotic category,” commented Dr Lucien Harthoorn, R&D Director at Clasado.
“For the first time, we have published data showing that Bimuno GOS, the most studied prebiotic of its kind, can provide a prebiotic effect at a dose compatible with ultra-low dose formats, such as capsules."
"From a formulation perspective, this expands what’s possible when creating gut health products supported by scientific evidence.
Although the standard 1.37 g/day dose of Bimuno GOS is already considered low for a prebiotic and is supported by a range of verified health benefits, we wanted to explore a lower dose option that still provides a bifidogenic effect; this study answers that.
It's about giving formulators more choice, more flexibility and more confidence to innovate with a proven prebiotic ingredient across a wider range of product formats.
Aurélien Baudot, CEO and founder at Cryptobiotix, added: “What’s most impressive is the strength and speed of the response shown in this study."
"The SIFR technology is unique in this respect. It lets you evaluate precisely the mechanism of action throughout the colonic fermentation and captures relevant outcomes even at low doses, both very important aspects here."
"At a dose as low as 380 mg of active GOS, Bimuno GOS clearly demonstrates a robust prebiotic effect, which opens innovation space for brands aiming to meet the demand for gut health solutions in more compact and convenient formats.”
As consumer interest in gut microbiome support continues to grow, the findings mark a pivotal step, offering formulators a low-dose prebiotic ingredient with scientific backing.